Ponesimod

CAT: 0804-HY-10569-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-10569-01Size:5 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Ponesimod (ACT-128800) is a potent, selective and orally active agonist of S1P1, with an IC50 of 6 nM in a radioligand binding assay. Ponesimod activates S1P1-mediated signal transduction with high potency (EC50=5.7 nM) . Ponesimod can protect against lymphocyte-mediated tissue inflammation[1][2][3].
CAS Number
[854107-55-4]
Product Name Alternative
ACT-128800
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
LPL Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/Ponesimod.html
Purity
99.78
Solubility
DMSO : ≥ 100 mg/mL
Smiles
O=C1N(C2=CC=CC=C2C)/C(S/C1=C\C3=CC=C(OC[C@H](O)CO)C(Cl)=C3)=N/CCC
Molecular Formula
C23H25ClN2O4S
Molecular Weight
460.97
Precautions
H302, H315, H319, H335
References & Citations
[1]Piali L, et al. The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation. J Pharmacol Exp Ther. 2011 May;337 (2) :547-56.|[2]Bolli MH, et al. 2-imino-thiazolidin-4-one derivatives as potent, orally active S1P1 receptor agonists. J Med Chem. 2010 May 27;53 (10) :4198-211.|[3]Brossard P, et al. Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-in-human study. Br J Clin Pharmacol. 2013 Dec;76 (6) :888-96.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
S1PR1; S1PR3; S1PR4; S1PR5

Popular Products